Abstract Library

#4549 Alpha-Fetoprotein as a valuable biomarker in neuroendocrine tumours

Introduction: Neuroendocrine tumours (NETs) are a rare group of tumours that pose a significant diagnostic, therapeutic, and prognostic challenge. This complexity arises from the diversity and heterogeneity of these neoplasms, as well as from the limitations of commonly used biomarkers in clinical practice. Alpha-fetoprotein (AFP) is a fetal protein widely used primarily for congenital defects in prenatal diagnostics and in certain malignancies in adults.

Conference:

Presenting Author:

Authors: Musiałkiewicz J, Gut P, Komarnicki P, Maciejewski A, Ruchała M,

Keywords: alpha-fetoprotein, biomarker, neuroendocrine tumour,

#4471 Acromegaly and small intestinal neuroendocrine tumours: Association or coincidence?

Introduction: Neuroendocrine tumours of the small intestine (SI-NETs), although rare, are the most prevalent primary neoplasms of this organ. Acromegaly is characterised by excessive secretion of growth hormone (GH), typically due to a pituitary adenoma, but in rare cases, it can result from ectopic secretion of GH-releasing hormone (GHRH) by non-pituitary tumours, particularly NETs of the lung or pancreas.

Conference:

Presenting Author: G. Martins R

Authors: Martins Fernandes A, Silva L, Serranito M, Elvas A, Santos J,

Keywords: neuroendocrine tumour, small intestinal neuroendocrine tumour, acromegaly,

#4363 61Cu-NODAGA-LM3 for the detection of neuroendocrine tumours: Preliminary results of the COPPER PET in NET trial, a randomised, crossover, readers blind, phase I/II non-inferiority study

Introduction: Currently approved PET tracers, Gallium-68 or Copper-64 labelled somatostatin receptor (SST) agonists (NETSPOT®, SOMAKIT® and Detecnet™), for imaging well-differentiated gastroenteropancreatic and bronchopulmonary neuroendocrine tumours (NET) have limitations. Radiolabelled SST antagonists offer superior imaging properties over agonists, and the combination with Copper-61, an unexplored PET isotope with a 3.33-hour half-life and favourable production characteristics, could be promising.

Conference:

Presenting Author: Nicolas G

Authors: Nicolas G, Chirindel A, Kaul F, Rommers N, Johayem A,

Keywords: Somatostatin Receptor PET/CT, Well-differentiated NEN, gastroenteropancreatic NET, bronchopulmonary NET, randomised controlled clinical trial, somatostatin receptor antagonist,

#4306 EVENET: Randomised phase II trial of everolimus 5mg vs. 10mg daily in patients with neuroendocrine tumours

Introduction: Everolimus 10mg PO daily is approved for patients (pts) with advanced G1/G2 neuroendocrine tumours (NET) but is associated with significant toxicity, including 20% of serious infections in real-world pts. In phase I trials, 5mg/day was sufficient to inhibit the mTOR pathway. Retrospective data suggest that 5mg/day is similarly effective to 10mg/day but less toxic.

Conference:

Presenting Author:

Authors: Riechelmann R, Campos A, Durant L, Bulzico D,

Keywords: everolimus, neuroendocrine tumour, dose optimisation, toxicity,

#4223 US real-world study of the burden of medication in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs)

Introduction: Patients with NETs experience a range of comorbidities, and often present with carcinoid syndrome (CS).

Conference:

Presenting Author:

Authors: Chan J, Houchard A, Pommie C, Ribeiro-Oliveira Jr A, Starr J,

Keywords: gastroenteropancreatic, neuroendocrine tumor, concomitant medication, burden,